Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group study (PE481)

Peter H. Wiernik, Dirk F. Moore, John M. Bennett, Steven E. Vogl, Jules E. Harris, Selina Luger, Martin M. Oken, John H. Glick

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Mitoguazone, an investigational agent with significant activity in advanced lymphoma, was added to a modified CHOP regimen (COPA) in an effort to improve the activity of standard therapy in 66 previously untreated patients with stages II-IV lymphoma and diffuse histology of intermediate or high grade other than lymphoblastic in this phase II pilot study. The regimen was well tolerated and the complete response rate in diffuse large cell lymphoma was 55%. Sixty-five percent of all complete responders were in complete response for at least one year. Despite these excellent results, it is unlikely that the addition of mitoguazone improved results compared with those obtained with standard therapy alone, since similar results have been frequently reported with the latter.

Original languageEnglish (US)
Pages (from-to)601-607
Number of pages7
JournalLeukemia and Lymphoma
Volume30
Issue number5-6
DOIs
StatePublished - 1998
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Keywords

  • CHOP
  • COPA
  • Lymphoma
  • Mitoguazone

Fingerprint Dive into the research topics of 'Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group study (PE481)'. Together they form a unique fingerprint.

Cite this